Treatment of fibrinolytic hemorrhage with proteinase inhibitors: a preliminary report.
D000614:Aminocaproates / Q000008:administration & dosage / Q000494:pharmacology; D000933:Antifibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007611:Aprotinin / Q000494:pharmacology; D001706:Biopsy; D001777:Blood Coagulation / Q000187:drug effects; D006348:Cardiac Surgical Procedures; D002648:Child; D005260:Female; D005341:Fibrinolysin / Q000494:pharmacology; D006417:Hematuria / Q000188:drug therapy; D006470:Hemorrhage / Q000188:drug therapy*; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications; D011183:Postoperative Complications; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D011517:Prothrombin Time; D013300:Streptokinase / Q000494:pharmacology; D014361:Trypsin Inhibitors / Q000494:pharmacology; D014566:Urogenital System
D000614:Aminocaproates; D000933:Antifibrinolytic Agents; D014361:Trypsin Inhibitors; D007611:Aprotinin; D013300:Streptokinase; D005341:Fibrinolysin